As of September 30, 2026, Kalaris Therapeutics, Inc. carries a market capitalization of 68.80M, placing it among publicly traded companies globally. Its enterprise value stands at -12.73M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.
| Market Cap | 68.80M |
| Enterprise Value | -12.73M |
Kalaris Therapeutics, Inc.'s next confirmed earnings release is scheduled for March 23, 2027.
| Earnings Date | 3/23/2027 |
As of September 30, 2026, Kalaris Therapeutics, Inc. has 23.80M shares outstanding.
| Shares Outstanding | 23.80M |
These figures are as of September 30, 2026.
| PB Ratio | 1.45 |
| P/TBV Ratio | 1.45 |
| P/FCF Ratio | -1.69 |
| P/OCF Ratio | -1.69 |
As of September 30, 2026, Kalaris Therapeutics, Inc. maintains a current ratio of 10.00, meaning it holds 10.0x the short-term assets needed to cover near-term liabilities.
| Current Ratio | 10.00 |
| Quick Ratio | 9.73 |
| Debt / Equity | 2.81 |
| Debt / EBITDA | -0.03 |
Over the twelve months ended September 30, 2026, Kalaris Therapeutics, Inc. posted a negative return on equity (ROE) of -97.23, meaning shareholder capital produced losses rather than profits. Return on assets (ROA) is negative at -51.00, reflecting losses generated across the asset base. The company generates approximately - - in revenue per employee across its workforce of 20.00, a quick read on workforce productivity versus industry peers.
| Return on Equity (ROE) | -97.23 |
| Return on Assets (ROA) | -51.00 |
| Employee Count | 20.00 |
As of the close on November 16, 2026, Kalaris Therapeutics, Inc.'s stock has declined approximately 73.26% over the past 52 weeks. The 50-day moving average sits at 2.49, while the 200-day moving average is 4.99.
| 52-Week Price Change | -73.26% |
| 50-Day Moving Average | 2.49 |
| 200-Day Moving Average | 4.99 |
Over the twelve months ended September 30, 2026, Kalaris Therapeutics, Inc. generated - - in revenue and converted that into -43.39M in net income, yielding earnings per share of -1.84. EBITDA reached -46.79M, while operating income came in at -46.83M.
| Operating Income | -46.83M |
| Pretax Income | -43.39M |
| Net Income | -43.39M |
| EBITDA | -46.79M |
| EBIT | -46.83M |
| Earnings Per Share (EPS) | -1.84 |
As of September 30, 2026, Kalaris Therapeutics, Inc. holds 82.86M in cash and equivalents against 1.33M in total debt, resulting in a net debt position of -47.38M. Total book value stands at 47.40M, with working capital of 76.66M providing operational flexibility.
| Cash & Cash Equivalents | 82.86M |
| Total Debt | 1.33M |
| Net Debt | -47.38M |
| Equity (Book Value) | 47.40M |
| Book Value Per Share | 1.99 |
| Working Capital | 76.66M |
Kalaris Therapeutics, Inc. produced -40.24M in operating cash flow over the twelve months ended September 30, 2026. After subtracting -17,000.00 in capital expenditures, free cash flow totaled -40.26M - equivalent to -1.71 per share.
| Operating Cash Flow | -40.24M |
| Capital Expenditures | -17,000.00 |
| Free Cash Flow | -40.26M |
| FCF Per Share | -1.71 |
These figures cover the twelve months ended September 30, 2026. Free cash flow yield is negative at -59.13: the business is consuming cash rather than generating it, so any dividend is not covered by free cash flow. Total shareholder yield is negative at -66.27, meaning Kalaris Therapeutics, Inc. raised more capital through share issuance and new debt than it returned via dividends and buybacks.
| Shareholder Yield | -66.27 |
| FCF Yield | -59.13 |
Kalaris Therapeutics, Inc.'s most recent stock split took place on January 16, 2025 with a 23:1 split ratio.
| Last Split Date | 1/16/2025 |
| Split Ratio | 23:1 |
As of September 30, 2026, Kalaris Therapeutics, Inc. has an Altman Z-Score of -2.75, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | -2.75 |